Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,002 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transmission of SARS-CoV-2 in Domestic Cats.
Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, Kinoshita N, Hattori SI, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Halfmann PJ, et al. Among authors: takeda m. N Engl J Med. 2020 Aug 6;383(6):592-594. doi: 10.1056/NEJMc2013400. Epub 2020 May 13. N Engl J Med. 2020. PMID: 32402157 Free PMC article. No abstract available.
The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses.
Sakai K, Ami Y, Tahara M, Kubota T, Anraku M, Abe M, Nakajima N, Sekizuka T, Shirato K, Suzaki Y, Ainai A, Nakatsu Y, Kanou K, Nakamura K, Suzuki T, Komase K, Nobusawa E, Maenaka K, Kuroda M, Hasegawa H, Kawaoka Y, Tashiro M, Takeda M. Sakai K, et al. Among authors: takeda m. J Virol. 2014 May;88(10):5608-16. doi: 10.1128/JVI.03677-13. Epub 2014 Mar 5. J Virol. 2014. PMID: 24600012 Free PMC article.
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.
Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T, Katoh H, Kato F, Sakata M, Tahara M, Kutsuna S, Ohmagari N, Kuroda M, Suzuki T, Kageyama T, Takeda M. Matsuyama S, et al. Among authors: takeda m. Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003. doi: 10.1073/pnas.2002589117. Epub 2020 Mar 12. Proc Natl Acad Sci U S A. 2020. PMID: 32165541 Free PMC article.
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. Yamamoto M, et al. Among authors: takeda m. Viruses. 2020 Jun 10;12(6):629. doi: 10.3390/v12060629. Viruses. 2020. PMID: 32532094 Free PMC article.
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.
Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M, Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H, Yasuhara A, Sakai-Tagawa Y, Lopes TJS, Kiso M, Yamayoshi S, Kinoshita N, Ohmagari N, Hattori SI, Takeda M, Mitsuya H, Krammer F, Suzuki T, Kawaoka Y. Imai M, et al. Among authors: takeda m. Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595. doi: 10.1073/pnas.2009799117. Epub 2020 Jun 22. Proc Natl Acad Sci U S A. 2020. PMID: 32571934 Free PMC article.
Proteolytic activation of SARS-CoV-2 spike protein.
Takeda M. Takeda M. Microbiol Immunol. 2022 Jan;66(1):15-23. doi: 10.1111/1348-0421.12945. Epub 2021 Oct 12. Microbiol Immunol. 2022. PMID: 34561887 Free PMC article. Review.
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: takeda m. N Engl J Med. 2022 Mar 10;386(10):995-998. doi: 10.1056/NEJMc2119407. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081300 Free PMC article. No abstract available.
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: takeda m. N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9. N Engl J Med. 2022. PMID: 35263535 Free PMC article. No abstract available.
Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.
Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, Ito M, Uraki R, Halfmann P, Watanabe S, Takeda M, Hasegawa H, Imai M, Kawaoka Y. Takashita E, et al. Among authors: takeda m. N Engl J Med. 2022 Sep 29;387(13):1236-1238. doi: 10.1056/NEJMc2209952. Epub 2022 Sep 7. N Engl J Med. 2022. PMID: 36121928 Free PMC article. No abstract available.
4,002 results